Helping patients reclaim a life of possibility
On September 17, 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of melphalan flufenamide (melflufen, Pepaxti®) to third-line myeloma treatment. The CHMP is the European Medicines Agency’s (EMA) committee responsible for evaluating medicines and making recommendations on whether they should be approved for use…
As the International Myeloma Society (IMS) Annual Meeting is taking place this week, we caught up with myeloma expert Dr. Faith Davies, from NYU Langone, about her expectations for the meeting and why it is important for patient advocacy groups like MPE to attend. What are you looking forward to most about IMS 2026? I…
We want to hear from people living with myeloma and their partners about how myeloma or its treatments have affected intimacy or sexual wellbeing and what information would be useful on this topic. Intimacy and sexual wellbeing can be difficult topics to talk about, but they are an important part of quality of life. Myeloma and…
Myeloma Melodies, an awareness concert for myeloma, returns to Paris on 24 September for an evening of singing, music and fun. The concert is organised by Sarah Tullamore, a professional singer, vocal coach and voice-over artist based in Paris, who is using her voice for a cause close to her heart: raising awareness of myeloma.…
September is shaping up to be an extraordinary month for myeloma awareness and advocacy across MPE’s member network. From Portugal to Serbia, from Lithuania to Slovenia, our members are planning bold, impactful campaigns to raise awareness during Blood Cancer Awareness Month and European Myeloma Day on 27 September. Key member activities include: Portugal (APCL) is…
Myeloma Patients Europe (MPE) is attending and presenting at the International Myeloma Society (IMS) Annual Meeting taking place in Glasgow from 23–26 September 2026. The meeting, attended by over 3,000 delegates from around the world, features presentations on the most important data and topics in myeloma. MPE recently interviewed IMS President and member of the…
As part of our September European Young Myeloma Patients Group (EYMPG) meeting on Induced Menopause and Sexual Health in young myeloma patients, Filipa Lopes has shared her personal experience of treatment induced menopause. She was diagnosed with myeloma at the age of 29 and hopes her story encourages other young patients to seek support and…
On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of teclistamab (Tecvayli®) to include its use in combination with daratumumab for adults with relapsed or refractory myeloma who have received at least one prior therapy. The CHMP is the European Medicines Agency’s (EMA) committee responsible for…